Dyslipidaemia has a prominent role in the onset of notorious atherosclerosis, a disease of medium to large arteries. Atherosclerosis is the prime root of cardiovascular events contributing to the most considerable number of morbidity and mortality worldwide. Factors like cellular senescence, genetics, clonal haematopoiesis, sedentary lifestyle‐induced obesity, or diabetes mellitus upsurge the tendency of atherosclerosis and are foremost pioneers to definitive transience. Accumulation of oxidized low‐density lipoproteins (Ox‐LDLs) in the tunica intima triggers the onset of this disease. In the later period of progression, the build‐up plaques rupture ensuing thrombosis (completely blocking the blood flow), causing myocardial infarction, stroke, and heart attack, all of which are common atherosclerotic cardiovascular events today. The underlying mechanism is very well elucidated in literature but the therapeutic measures remains to be unleashed. Researchers tussle to demonstrate a clear understanding of treating mechanisms. A century of research suggests that lowering LDL, statin‐mediated treatment, HDL, and lipid‐profile management should be of prime interest to retard atherosclerosis‐induced deaths. We shall brief the Ox‐LDL‐induced atherogenic mechanism and the treating measures in line to impede the development and progression of atherosclerosis.